Phenylketonuria And Mental Health
Published on: March 13, 2025
phenylketonuria and mental health

Introduction

Phenylketonuria (PKU) is a common disorder caused by a problem in amino acid metabolism. It happens due to changes in the phenylalanine hydroxylase (PAH) gene. This condition makes it hard for the body to break down phenylalanine, an amino acid in many foods. PKU can range from a mild increase in blood phenylalanine levels to a severe form called classic PKU, which, if untreated, can cause serious and permanent mental disabilities.

Newborns are usually screened for PKU, and if it’s detected early, starting a diet low in phenylalanine can prevent most mental health issues. However, sticking to this diet can be tough, especially for teens, young adults, and pregnant women. Some patients (about 20%) respond well to tetrahydrobiopterin, which helps the body process phenylalanine better and gives a bit more dietary freedom. Future treatments being looked into include enzyme replacement and gene therapy, aiming to restore normal phenylalanine processing in the body.1,2

Importance of mental health in PKU

Phenylketonuria (PKU) is a genetic disorder that affects how the body processes the amino acid phenylalanine. When phenylalanine builds up in the brain, it can lead to low levels of neurotransmitters like dopamine and serotonin, which are crucial for mood and cognitive functions. This can result in problems with executive functions, such as planning and decision-making, as well as mood disorders like depression and anxiety.

This article explores the mental health challenges faced by people with PKU, especially focusing on how early and continuous treatment impacts their cognitive abilities and overall mental well-being. It highlights findings from the PKU-COBESO study, which investigates the connection between metabolic control and mental health outcomes in PKU patients. The study looks at cognitive functions, behavioral issues, and social skills, aiming to provide a comprehensive understanding of how PKU affects mental health.3,4

Genetic basis of PKU

Phenylketonuria (PKU) happens because of a mutation in the PAH gene. This gene is supposed to make an enzyme called phenylalanine hydroxylase. During mutation, the enzyme doesn’t work right or is made at all. This means the body can't break down phenylalanine, an amino acid found in many foods. When phenylalanine builds up, it can cause serious brain damage and other health problems.5

How PKU is inherited (Autosomal Recessive Pattern)

PKU is inherited in an autosomal recessive pattern. This means a person needs to get a copy of the mutated gene from both parents to have the disorder. If they get only one mutated gene, they won't have PKU but will be a carrier. If both parents are carriers, there’s a 25% chance their child will have PKU, a 50% chance their child will be a carrier, and a 25% chance their child will neither have PKU nor be a carrier.6,7

Biochemical impact

Phenylketonuria (PKU) happens because a person’s body can’t break down an amino acid called phenylalanine (Phe). Normally, phenylalanine gets converted into another amino acid, tyrosine, by an enzyme called phenylalanine hydroxylase. In people with PKU, this enzyme doesn’t work properly. So, phenylalanine builds up in the body instead of getting processed.

Effects of high phenylalanine levels on the brain and overall health

When phenylalanine levels get too high, it messes with the brain’s ability to get other important amino acids. This can cause damage to the brain and lead to various problems. In particular, it can affect mental functions and lead to issues like slower thinking and mood changes. Long-term high levels of phenylalanine can result in severe cognitive and developmental issues, which is why people with PKU have to stick to a special diet to keep their phenylalanine levels in check.8

Symptoms of PKU

Phenylketonuria (PKU) comes with a mix of symptoms, both physical and neurological.

Common physical symptoms

In phenylketonuria (PKU), some common physical symptoms include vomiting, which affects more than half of the patients early in life. Infantile eczema, a type of skin rash, also occurs in some cases. Additionally, a peculiar smell from the body or urine is often noticed. Sometimes, patients might also experience pyloric stenosis, where the passage from the stomach to the small intestine is narrowed.9

Neurological symptoms

Neurologically, PKU can lead to a variety of issues. Early on, babies might show irritability, which means they’re unusually fussy or difficult to soothe. As they grow, if untreated, PKU can result in severe mental and behavioral problems. In adults, there’s a higher risk of psychiatric symptoms like anxiety, depression, and even psychotic symptoms. These issues are linked to the levels of phenylalanine (phe) in the blood, as high levels can affect brain function and lead to various cognitive and emotional disturbances.10

Mental health aspects of PKU

PKU can cause several cognitive challenges, including learning difficulties and intellectual disabilities. People with PKU may struggle with memory, attention, and executive functioning. For instance, focus on tasks, remember details, or make decisions effectively.

The impact on memory means they could forget information more easily or have trouble recalling it when needed. Attention issues can make it tough to stay engaged in conversations or complete tasks without getting distracted. Executive functioning problems may affect their ability to plan, organize, and execute tasks in a logical sequence.

Even with dietary treatment from birth, these cognitive issues can still be present, often creating a noticeable gap compared to non-PKU peers. The diet helps manage the condition but doesn’t completely eliminate all cognitive challenges.11

Emotional and behavioral issues

For people with PKU who started treatment early, anxiety and depression are notable concerns. The review of 17 studies found that PKU patients often show higher levels of depression and anxiety compared to people without PKU. However, it’s tough to pinpoint exactly how severe these issues are due to limitations in the study designs.

When it comes to behavioral problems, PKU patients may also experience issues like hyperactivity and mood swings. This aligns with findings from the current study, where the PKU group faced challenges in perspective-taking and experienced more distress in social situations. Moreover, difficulties in sticking to the PKU diet were linked to lower emotional well-being. Overall, while cognitive issues like attention and executive function are documented, emotional difficulties like anxiety and depression also seem to be a significant part of the PKU experience.12

Social challenges

People with PKU often face social challenges despite early treatment. They can struggle with social interactions and building relationships. This might be due to subtle cognitive issues or executive function deficits that aren't always obvious. These difficulties can make it hard for them to connect with others and can affect their ability to form lasting friendships or romantic relationships.

The impact on self-esteem can be significant. Because they might not always fit in or engage as easily as others, they may feel less confident about themselves. This can also affect their social participation, making them less likely to join in activities or social events. Essentially, while PKU treatment helps with severe symptoms, these hidden issues can still pose challenges in everyday social situations.13

Managing PKU and mental health

Dietary management

  • Low-Phenylalanine Diet: Sticking to a diet low in phenylalanine (Phe) is crucial because high Phe levels can harm the brain and lead to mental health issues
  • Specialized Formulas: Special formulas and food products help patients get the nutrients they need while keeping Phe levels in check
  • Long-Term Adherence: Following this strict diet is tough, especially as patients age. They might struggle with maintaining dietary restrictions over time

Medical treatments

Current and Emerging Treatments: Managing PKU mostly involves dietary control. New treatments like enzyme replacement and gene therapy are continuing but aren’t widely available yet.

Regular Monitoring: Keeping track of Phe levels regularly is key to managing PKU and preventing complications.14

Psychological support

Mental Health Support: Since PKU can impact mental health, getting counseling and support is important.

Managing Stress: Strategies like therapy and stress management techniques can help with anxiety, depression, and other mental health issues.15

Summary

Phenylketonuria (PKU) is a disorder caused by a change in the PAH gene, which makes it hard for the body to break down phenylalanine, an amino acid in many foods. If untreated, high levels of phenylalanine can lead to severe mental disabilities. Early detection through newborn screening and a strict diet low in phenylalanine can prevent most of these issues, but sticking to this diet can be challenging, especially for teens, young adults, and pregnant women. Some patients benefit from tetrahydrobiopterin, which helps manage phenylalanine levels better, giving them more dietary freedom. Research on enzyme replacement and gene therapy is in progress.

PKU not only affects physical health but also has significant mental health implications. High phenylalanine levels can lead to problems with neurotransmitters like dopamine and serotonin, impacting mood and cognitive functions. This can cause issues with memory, attention, and executive functioning, as well as mood disorders such as anxiety and depression. Even with dietary management, these cognitive and emotional challenges can persist.

Socially, people with PKU might struggle with interactions and forming relationships, partly due to these hidden cognitive issues. Managing PKU involves strict dietary control, specialized formulas, and regular monitoring of phenylalanine levels. Emerging treatments are in development, but currently, psychological support and stress management are crucial to addressing the mental health challenges associated with PKU.

References

  • Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. The Lancet. 2010 Oct 23;376(9750):1417-27
  • van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers [Internet]. 2021 May 20 [cited 2024 Jul 25];7(1):1–19. Available from: https://www.nature.com/articles/s41572-021-00267-0
  • Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Bosch AM, Hollak CEM, et al. Mental health and social functioning in early treated Phenylketonuria: The PKU-COBESO study. Molecular Genetics and Metabolism [Internet]. 2013 Jan 1 [cited 2024 Jul 25];110:S57–61. Available from: https://www.sciencedirect.com/science/article/pii/S1096719213003594
  • Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, et al. Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study. Neuropsychology. 2017;31(4):437–47.
  • Jahja R, van Spronsen FJ, de Sonneville LMJ, van der Meere JJ, Bosch AM, Hollak CEM, et al. Long-term follow-up of cognition and mental health in adult phenylketonuria: a pku-cobeso study. Behav Genet [Internet]. 2017 Sep 1 [cited 2024 Jul 25];47(5):486–97. Available from: https://doi.org/10.1007/s10519-017-9863-1
  • Blau N. Genetics of phenylketonuria: then and now. Human Mutation [Internet]. 2016 Jun [cited 2024 Jul 25];37(6):508–15. Available from: https://onlinelibrary.wiley.com/doi/10.1002/humu.22980
  • Clacy A, Sharman R, McGill J. Depression, anxiety, and stress in young adults with phenylketonuria: associations with biochemistry. Journal of Developmental & Behavioral Pediatrics. 2014 Jul 1;35(6):388-91.
  • Alptekin IM, Koc N, Gunduz M, Cakiroglu FP. The impact of phenylketonuria on PKU patients’ quality of life: Using of the phenylketonuria-quality of life (Pku-qol) questionnaires. Clinical Nutrition ESPEN [Internet]. 2018 Oct 1 [cited 2024 Jul 25];27:79–85. Available from: https://www.sciencedirect.com/science/article/pii/S2405457718303577
  • [cited 2024 Jul 25]. Available from: https://publications.aap.org/pediatrics/article-abstract/27/3/465/41073/THE-EARLY-SYMPTOMS-OF-PHENYLKETONURIA?autologincheck=redirected
  • Bilder DA, Burton BK, Coon H, Leviton L, Ashworth J, Lundy BD, et al. Psychiatric symptoms in adults with phenylketonuria. Molecular Genetics and Metabolism [Internet]. 2013 Mar 1 [cited 2024 Jul 25];108(3):155–60. Available from: https://www.sciencedirect.com/science/article/pii/S1096719212007196
  • Ashe K, Kelso W, Farrand S, Panetta J, Fazio T, De Jong G, et al. Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments. Front Psychiatry [Internet]. 2019 Sep 10 [cited 2024 Jul 25];10. Available from: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2019.00561/full
  • Palermo L, MacDonald A, Limback E, Robertson L, Howe S, Geberhiwot T, et al. Emotional health in early-treated adults with phenylketonuria (Pku): Relationship with cognitive abilities and blood phenylalanine. Journal of Clinical and Experimental Neuropsychology [Internet]. 2020 Feb 7 [cited 2024 Jul 25];42(2):142–59. Available from: https://www.tandfonline.com/doi/full/10.1080/13803395.2019.1696753
  • Burton BK, Hermida Á, Bélanger-Quintana A, Bell H, Bjoraker KJ, Christ SE, et al. Management of early treated adolescents and young adults with phenylketonuria: Development of international consensus recommendations using a modified Delphi approach. Molecular Genetics and Metabolism [Internet]. 2022 Sep 1 [cited 2024 Jul 25];137(1):114–26. Available from: https://www.sciencedirect.com/science/article/pii/S1096719222003729
  • Altman G, Hussain K, Green D, Strauss BJG, Wilcox G. Mental health diagnoses in adults with phenylketonuria: a retrospective systematic audit in a large UK single centre. Orphanet J Rare Dis [Internet]. 2021 Dec 20 [cited 2024 Jul 25];16(1):520. Available from: https://doi.org/10.1186/s13023-021-02138-z
  • Jahja R, van Spronsen FJ, de Sonneville LMJ, van der Meere JJ, Bosch AM, Hollak CEM, et al. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study. J Inherit Metab Dis [Internet]. 2016 May 1 [cited 2024 Jul 25];39(3):355–62. Available from: https://doi.org/10.1007/s10545-016-9918-0
Share

Susmita Bhandary

Master's of pharmacy - M.Pharm, Pharmacology, Roland Institute of Pharmaceutical Sciences (RIPS), Berhampur

I am a certified medical writer with a background in M.Pharm. (pharmacology) and extensive hands-on experience in medical and scientific writing. My prior experience includes pharmacovigilance, clinical analysis, and medical transcription. Besides that, I worked at different organizations as a medical content writer and medical journalist, which included the creation of clear, concise, and elaborated medical content with in-depth information for various target audiences.

I am dedicated to crafting quality health content. My academic achievements, combined with my practical experience, have improved my skills in medical writing. I have several month experience in medical content writing.

arrow-right